A phase I/II clinical study of oral lenalidomide + rituximab for relapsed refractory set of lymphomas (MCL) reported by M. Wang from MD Anderson Cancer Center showed that oral lenalidomide + rituximab prolonged the remission period in MCL patients. The study enrolled 52 patients who were given oral lenalidomide 10-25 mg/d for 21 days, followed by a 7-day break, in cycles of 28 days, and an intravenous infusion of rituximab, 375 mg/m2, once weekly for 4 weeks during the first cycle of lenalidomide administration. Lenalidomide was applied continuously until disease progression or serious adverse effects occurred. The results showed an overall effective rate of 57.8%, a complete remission rate of 32.6%, a median remission period of 18.9 months, and a median progression-free survival time of 13 months. The mean follow-up was 23.1 months, with a median overall survival of 25.1 months. The combination regimen was well tolerated, and common grade 3 to 4 toxicities included neutropenia, lymphocytopenia and thrombocytopenia. The investigators noted that oral lenalidomide + rituximab for relapsed refractory MCL was well tolerated and had a very high efficacy.